Recent NRBO Stock Price | NRBO Stock Predictions | |
$3.46 | +954.91% |
$36.50 |
Recent NRBO Analyst Ratings Breakdown, Making NRBO Stock Predictions | ||||
---|---|---|---|---|
Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | |
Strong buy ratings: | 1 | 1 | 1 | 1 |
Buy ratings: | 0 | 0 | 0 | 0 |
Hold ratings: | 0 | 0 | 0 | 0 |
Sell ratings: | 0 | 0 | 0 | 0 |
Strong sell ratings: | 0 | 0 | 0 | 0 |
Average rating: | 1.0 | 1.0 | 1.0 | 1.0 |
For the NRBO stock predictions from the analysts covering NeuroBo Pharmaceuticals Inc, we have collected all of the individual NRBO stock predictions for stock price one year from now (i.e. each analyst's "forward price target") and at the top of this page we have presented the average prediction across the 2 different analysts covering NRBO (as reported in
data provided by Zacks Investment Research via Quandl.com).
But since NRBO stock predictions may vary widely, another useful metric to consider is the median NRBO stock prediction, which represents the price at which half of the analysts
made NRBO stock predictions that were higher and half made NRBO stock predictions that were lower. This makes for a different take on the NRBO stock predictions out there, as compared to average or mean.
And that median across all the individual NRBO stock predictions was: $36.5 as of 2024-04-18.
The very highest of the NRBO stock predictions for one year price target was $48.0, while the very lowest of the NRBO stock predictions in the analyst group was
$25.0 (with a standard deviation of $16.263). Get the latest Zacks research report on NRBO — FREE
Dividend Growth Stocks: 25 Aristocrats
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Other stock predictions:
PZZA Stock Predictions
PEAK Stock Predictions
MANT Stock Predictions
ATH Stock Predictions
COTY Stock Predictions
RCL Stock Predictions
SNN Stock Predictions
TACO Stock Predictions
YMAB Stock Predictions
|
|
Strong Buy (4.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |